Aurealis Therapeutics offers a 4‑in‑1 multi‑target cell and gene therapy platform that creates engineered cellular products to modulate the tissue microenvironment and address multiple disease pathways in one treatment. The platform is used to develop therapies for chronic non‑healing wounds such as diabetic foot and venous leg ulcers, as well as aggressive solid tumors, with pre‑clinical and Phase 2 clinical data supporting safety, efficacy, and cost‑effectiveness.

Civi is a security application that delivers real-time security alerts through a network of monitored sensors and data analytics. It addresses the need for immediate threat detection, enabling users to respond swiftly to potential security breaches.

DIA provides a decentralized oracle platform that utilizes a rollup architecture to deliver real-time, verifiable data across over 50 blockchain networks, supporting more than 20,000 assets. This technology addresses the need for reliable and transparent data feeds in decentralized applications, enabling developers to integrate accurate price information without relying on third-party sources.

Index provides an all-in-one analytics platform that connects disparate data sources for unified querying. Its core feature leverages AI to translate natural language questions directly into executable SQL queries and visualizations. The platform enables automated sharing of up-to-date metrics and insights via dashboards and direct integrations with collaboration tools like Slack.

Provides a cloud-based platform that uses computer vision and AI to automate camera control, enabling real-time framing, tracking, and image adjustments without manual presets or hardware. It streamlines video production workflows by offering features like auto-tracking, remote monitoring, and seamless integration with tools like OBS and vMIX, reducing setup time and improving consistency across shoots.

Marius Pharmaceuticals develops KYZATREX, an oral testosterone undecanoate therapy absorbed primarily via the lymphatic system, designed to treat adult men with hypogonadism, a condition characterized by low testosterone levels. This therapy addresses the significant health impacts of testosterone deficiency, including fatigue, decreased libido, and increased risk of metabolic disorders, by restoring testosterone levels to the normal range in a majority of patients.

Novuson develops patented Direct Therapeutic Ultrasound (DTU) technology for advanced energy applications in surgery. This innovation targets vessel sealing, dividing, soft tissue ablation, and hemostasis without passing electric current through the patient. Their device portfolio includes specialized sealers and dividers designed to improve efficiency and patient outcomes in surgical and trauma settings.

Re is an on‑chain reinsurance protocol that tokenizes real reinsurance treaties, issuing fully collateralized tokens backed by verified insurance premiums. The platform provides institutional investors and insurers with regulated, transparent access to the $800B+ reinsurance market, delivering 8‑16% annual yields that are largely uncorrelated with traditional assets while maintaining defined risk limits and underwriting discipline.

This pharmaceutical company specializes in a patented sublingual drug-delivery system designed for opioid cessation and non-addictive pain management solutions. By integrating proprietary technology with manufacturing and distribution capabilities, the company aims to provide effective alternatives to traditional opioid treatments.